

# Thomas A Ciulla

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/266684/thomas-a-ciulla-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186  
papers

10,786  
citations

50  
h-index

101  
g-index

201  
ext. papers

12,376  
ext. citations

5.5  
avg, IF

6.28  
L-index

#	Paper	IF	Citations
186	Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.. <i>Annals of Medicine</i> , <b>2022</b> , 54, 343-358	1.5	1
185	Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. <i>British Journal of Ophthalmology</i> , <b>2021</b> , 105, 1696-1704	5.5	4
184	Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis. <i>Ophthalmology Retina</i> , <b>2021</b> , 5, 633-647	3.8	3
183	Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). <i>British Journal of Ophthalmology</i> , <b>2021</b> ,	5.5	2
182	Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits. <i>Translational Vision Science and Technology</i> , <b>2021</b> , 10, 19	3.3	0
181	Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World. <i>Genes</i> , <b>2021</b> , 12,	4.2	3
180	Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes. <i>Human Gene Therapy</i> , <b>2021</b> , 32, 682-693	4.8	12
179	Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. <i>British Journal of Ophthalmology</i> , <b>2021</b> , 105, 216-221	5.5	24
178	Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. <i>Ophthalmology Retina</i> , <b>2021</b> , 5, 60-70	3.8	10
177	Microbial Spectrum and Antibacterial Susceptibility of Endophthalmitis Cultures in a Tertiary Referral Center in the Midwestern United States: An Analysis From 295 Patients. <i>Journal of Vitreoretinal Diseases</i> , <b>2021</b> , 5, 216-220	0.7	
176	RNA therapeutics for retinal diseases. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 603-613	5.4	6
175	Delivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies. <i>International Ophthalmology Clinics</i> , <b>2021</b> , 61, 35-57	1.7	1
174	DNA- and RNA-based Gene Therapies in Ophthalmology. <i>International Ophthalmology Clinics</i> , <b>2021</b> , 61, 3-16	1.7	1
173	Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). <i>British Journal of Ophthalmology</i> , <b>2021</b> ,	5.5	4
172	Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	8
171	Understanding the genetic pathology of Stargardt disease: a review of current findings and challenges. <i>Expert Opinion on Orphan Drugs</i> , <b>2021</b> , 9, 35-44	1.1	1
170	Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment. <i>Clinical Interventions in Aging</i> , <b>2021</b> , 16, 1367-1378	4	2

169	Glaucoma Heritability: Molecular Mechanisms of Disease. <i>Genes</i> , <b>2021</b> , 12,	4.2	4
168	Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases. <i>American Journal of Ophthalmology</i> , <b>2021</b> , 235, 90-97	4.9	4
167	Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial. <i>Ocular Immunology and Inflammation</i> , <b>2021</b> , 1-8	2.8	0
166	Physics-based modeling of Age-related Macular Degeneration-A theoretical approach to quantify retinal and choroidal contributions to macular oxygenation. <i>Mathematical Biosciences</i> , <b>2021</b> , 339, 108650	3.9	1
165	RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies. <i>International Ophthalmology Clinics</i> , <b>2021</b> , 61, 125-132	1.7	0
164	Genes and Gene Therapy in Inherited Retinal Disease. <i>International Ophthalmology Clinics</i> , <b>2021</b> , 61, 3-45	1.7	0
163	Genetic Testing Prevalence, Guidelines, and Pitfalls in Large, University-Based Medical Systems. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2021</b> , 52, 6-10	1.4	2
162	Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies. <i>Expert Opinion on Drug Delivery</i> , <b>2021</b> , 18, 777-788	8	6
161	Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders. <i>Translational Vision Science and Technology</i> , <b>2020</b> , 9, 27	3.3	5
160	Voretigene neparvovec-rzyl for treatment of -mediated inherited retinal diseases: a model for ocular gene therapy development. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 565-578	5.4	20
159	Retinal oximetry in glaucoma: investigations and findings reviewed. <i>Acta Ophthalmologica</i> , <b>2020</b> , 98, 559-571	3.7	8
158	Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. <i>Ophthalmology</i> , <b>2020</b> , 127, 948-955	7.3	46
157	Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2020</b> , 36, 384-392	2.6	20
156	Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium/Choroid in Rabbits. <i>Translational Vision Science and Technology</i> , <b>2020</b> , 9, 21	3.3	10
155	Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations. <i>Genes</i> , <b>2020</b> , 12,	4.2	14
154	Evolution of Primary Scleral Buckling Surgery: A Modified Lean Six Sigma Technique to Improve Surgical Efficiency. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2020</b> , 51, 256-261	1.4	1
153	Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 237-244	5.9	10
152	Anti-integrin therapy for retinovascular diseases. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 935-945	5.5	13

151	Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes. <i>Ophthalmology Retina</i> , <b>2020</b> , 4, 19-30	3.8	49
150	Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 861-869	5.9	40
149	Estimation of impact of mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. <i>British Journal of Ophthalmology</i> , <b>2019</b> , 103, 1610-1614	5.5	25
148	Complement inhibition as a therapeutic strategy in retinal disorders. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 335-342	5.4	54
147	Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies. <i>Value in Health</i> , <b>2019</b> , 22, 970-971	3.3	4
146	Vascular dysfunction in retinitis pigmentosa. <i>Acta Ophthalmologica</i> , <b>2019</b> , 97, 660-664	3.7	10
145	Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1703-1709	4	5
144	Innovative therapies for neovascular age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1879-1891	4	56
143	Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease. <i>JAMA Ophthalmology</i> , <b>2019</b> , 137, 1115-1123	3.9	26
142	Vitreous Physiology. <i>Modeling and Simulation in Science, Engineering and Technology</i> , <b>2019</b> , 267-275	0.8	
141	Vitreous Pathology. <i>Modeling and Simulation in Science, Engineering and Technology</i> , <b>2019</b> , 277-287	0.8	2
140	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. <i>BMJ Open Ophthalmology</i> , <b>2019</b> , 4, e000398	3.2	38
139	Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , <b>2018</b> , 136, 337-345	3.9	17
138	Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States. <i>Ophthalmology Retina</i> , <b>2018</b> , 2, 645-653	3.8	36
137	Pharmacotherapy of retinal disease with visual cycle modulators. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 471-481	4	22
136	EFFICACY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR REFRACTORY MACULAR EDEMA CAUSED BY RETINAL VEIN OCCLUSION. <i>Retinal Cases and Brief Reports</i> , <b>2018</b> , 12, 294-299	1.1	2
135	LEAN SIX SIGMA TECHNIQUES TO IMPROVE OPHTHALMOLOGY CLINIC EFFICIENCY. <i>Retina</i> , <b>2018</b> , 38, 1688-1698	3.6	21
134	Gene therapy for inherited retinal and optic nerve degenerations. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 37-49	5.4	55

133	The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review. <i>Survey of Ophthalmology</i> , <b>2018</b> , 63, 281-295	6.1	34
132	Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. <i>Ophthalmology Retina</i> , <b>2018</b> , 2, 1179-1187	3.8	54
131	Stargardt macular dystrophy and evolving therapies. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 1049-1059	5.1	29
130	Vital Dyes in Vitreomacular Surgery. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2018</b> , 49, 788-798	1.4	7
129	Treatment Burden in Neovascular AMD: Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2017</b> , 48, 780-784	1.4	20
128	Gene therapy for age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 1235-1244	5.1	40
127	Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. <i>Expert Opinion on Emerging Drugs</i> , <b>2017</b> , 22, 235-246	3.7	57
126	Induced pluripotent stem cell-based therapy for age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 1113-1126	5.4	22
125	Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. <i>Ophthalmology</i> , <b>2017</b> , 124, 224-234	7.3	81
124	RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS. <i>Retina</i> , <b>2016</b> , 36, 1292-7	3.6	18
123	Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 365-74	5.4	52
122	Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , <b>2015</b> , 122, 1846-53.e5	7.3	96
121	Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , <b>2015</b> , 122, 1203-11	7.3	43
120	Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. <i>Eye</i> , <b>2014</b> , 28, 269-78	4.4	49
119	Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 953-9	4	35
118	Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , <b>2014</b> , 98, 172-8	5.5	20
117	Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. <i>Ophthalmology</i> , <b>2013</b> , 120, 1843-51	7.3	153
116	Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. <i>Ophthalmology</i> , <b>2013</b> , 120, 583-587	7.3	90

115	Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2013</b> , 44, 17-21	1.4	13
114	Impaired ocular blood flow regulation in patients with open-angle glaucoma and diabetes. <i>Clinical and Experimental Ophthalmology</i> , <b>2012</b> , 40, 697-705	2.4	26
113	Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 606-15	59.2	428
112	Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. <i>Ophthalmology</i> , <b>2011</b> , 118, 111-8	7.3	43
111	Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. <i>Ophthalmology</i> , <b>2011</b> , 118, 626-635.e2	7.3	288
110	Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. <i>Ophthalmology</i> , <b>2011</b> , 118, 1089-97	7.3	84
109	Ranibizumab and bevacizumab for neovascular age-related macular degeneration. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1897-908	59.2	1923
108	Patient preferences in the treatment of diabetic retinopathy. <i>Patient Preference and Adherence</i> , <b>2011</b> , 5, 229-37	2.4	7
107	Response to: Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion by Schroff et al. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2011</b> , 249, 305	3.8	
106	Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 947-56	11.6	47
105	Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. <i>Ophthalmology</i> , <b>2010</b> , 117, 1393-9.e3	7.3	122
104	Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. <i>Ophthalmology</i> , <b>2010</b> , 117, 2146-51	7.3	419
103	Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. <i>Acta Ophthalmologica</i> , <b>2010</b> , 88, 279-91	3.7	90
102	Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2010</b> , 248, 375-80	3.8	28
101	Antivasular endothelial growth factor therapy for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , <b>2009</b> , 20, 158-65	5.1	91
100	Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome. <i>Retina</i> , <b>2009</b> , 29, 1418-23	3.6	17
99	Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , <b>2009</b> , 20, 166-74	5.1	73
98	Age-related macular degeneration and the aging eye. <i>Clinical Interventions in Aging</i> , <b>2008</b> , 3, 473-82	4	65

97	How the diabetic eye loses vision. <i>Endocrine</i> , <b>2007</b> , 32, 107-16		48
96	Therapeutic effects of ranibizumab in neovascular age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , <b>2007</b> , 2, 679-693	1.5	
95	Sustained response to multiple intravitreal triamcinolone acetonide injections in a patient with predominantly occult choroidal neovascularization. <i>Retinal Cases and Brief Reports</i> , <b>2007</b> , 1, 12-3	1.1	
94	Squalamine lactate for the treatment of age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , <b>2007</b> , 2, 165-175	1.5	8
93	Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. <i>Clinical Ophthalmology</i> , <b>2007</b> , 1, 383-91	2.5	17
92	The relationship between retrobulbar and choroidal hemodynamics in non-neovascular age-related macular degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2007</b> , 38, 219-25	1.4	5
91	Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. <i>JAMA Ophthalmology</i> , <b>2006</b> , 124, 1532-42		220
90	Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. <i>Ophthalmology</i> , <b>2006</b> , 113, 633.e1-4	7.3	312
89	Retinal and Choroidal Blood Flow in Health and Disease <b>2006</b> , 83-102		10
88	Corticosteroids as antiangiogenic agents. <i>Ophthalmology Clinics of North America</i> , <b>2006</b> , 19, 345-51, v		15
87	Human vitreous distribution of linezolid after a single oral dose. <i>Retina</i> , <b>2005</b> , 25, 619-24	3.6	14
86	Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model. <i>Retina</i> , <b>2005</b> , 25, 1054-64	3.6	24
85	New and classic insights into presumed ocular histoplasmosis syndrome and its treatment. <i>Current Opinion in Ophthalmology</i> , <b>2005</b> , 16, 160-5	5.1	20
84	Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. <i>Expert Opinion on Emerging Drugs</i> , <b>2005</b> , 10, 119-35	3.7	3
83	Photodynamic therapy with PhotoPoint photosensitizer MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. <i>British Journal of Ophthalmology</i> , <b>2005</b> , 89, 113-9	5.5	17
82	Anastomotic vessels remain viable after photodynamic therapy in primate models of choroidal neovascularization. <i>Investigative Ophthalmology and Visual Science</i> , <b>2005</b> , 46, 2168-74		12
81	Current and future pharmacological intervention for diabetic retinopathy. <i>Expert Opinion on Emerging Drugs</i> , <b>2005</b> , 10, 441-55	3.7	12
80	The squirrel monkey: characterization of a new-world primate model of experimental choroidal neovascularization and comparison with the macaque. <i>Investigative Ophthalmology and Visual Science</i> , <b>2004</b> , 45, 625-34		14

79	Current and future treatment options for nonexudative and exudative age-related macular degeneration. <i>Drugs and Aging</i> , <b>2004</b> , 21, 967-92	4.7	25
78	Laser trabecular sclerosis for chronic hypotony after vitreoretinal surgery. <i>Ophthalmology</i> , <b>2004</b> , 111, 256-8	7.3	3
77	Macular pigment density and aging, assessed in the normal elderly and those with cataracts and age-related macular degeneration. <i>American Journal of Ophthalmology</i> , <b>2004</b> , 138, 582-7	4.9	70
76	Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. <i>Current Opinion in Ophthalmology</i> , <b>2004</b> , 15, 211-20	5.1	80
75	Pharmacotherapy for diabetic retinopathy. <i>Current Opinion in Ophthalmology</i> , <b>2004</b> , 15, 508-18	5.1	45
74	Evaluation of photopoint photosensitizer mv6401, indium chloride methyl pyropheophorbide, as a photodynamic therapy agent in primate choriocapillaris and laser-induced choroidal neovascularization. <i>Retina</i> , <b>2004</b> , 24, 521-9	3.6	4
73	Diagnostic imaging of retinal disease. <i>International Ophthalmology Clinics</i> , <b>2004</b> , 44, 1-15	1.7	25
72	The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration. <i>British Journal of Ophthalmology</i> , <b>2003</b> , 87, 753-7	5.5	9
71	Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. <i>Retina</i> , <b>2003</b> , 23, 808-14	3.6	54
70	Leber congenital amaurosis associated with optic disk neovascularization and vitreous hemorrhage. <i>American Journal of Ophthalmology</i> , <b>2003</b> , 135, 723-5	4.9	4
69	Bacterial endophthalmitis prophylaxis. <i>Ophthalmology</i> , <b>2003</b> , 110, 1667; author reply 1667-8	7.3	
68	Bacterial endophthalmitis prophylaxis: Author reply. <i>Ophthalmology</i> , <b>2003</b> , 110, 1667-1668	7.3	
67	Bacterial endophthalmitis prophylaxis: Author reply. <i>Ophthalmology</i> , <b>2003</b> , 110, 1669	7.3	
66	Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. <i>Diabetes Care</i> , <b>2003</b> , 26, 2653-64	14.6	539
65	Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. <i>British Journal of Ophthalmology</i> , <b>2003</b> , 87, 1032-7	5.5	57
64	Ocular perfusion abnormalities in diabetes. <i>Acta Ophthalmologica</i> , <b>2002</b> , 80, 468-77		94
63	An update on photodynamic therapy in age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , <b>2002</b> , 3, 931-8	4	27
62	Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. <i>British Journal of Ophthalmology</i> , <b>2002</b> , 86, 527-9	5.5	73



61	Choroidal perfusion perturbations in non-neovascular age related macular degeneration. <i>British Journal of Ophthalmology</i> , <b>2002</b> , 86, 209-13	5.5	60
60	Novel approaches for retinal drug delivery. <i>Ophthalmology Clinics of North America</i> , <b>2002</b> , 15, 405-10		40
59	Localization of rose bengal, aluminum phthalocyanine tetrasulfonate, and chlorin e6 in the rabbit eye. <i>Retina</i> , <b>2002</b> , 22, 65-74	3.6	13
58	Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. <i>American Journal of Ophthalmology</i> , <b>2002</b> , 134, 905-6	4.9	40
57	Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. <i>Ophthalmology</i> , <b>2002</b> , 109, 13-24	7.3	356
56	Macular pigment density is reduced in obese subjects. <i>Investigative Ophthalmology and Visual Science</i> , <b>2002</b> , 43, 47-50		79
55	Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. <i>JAMA Ophthalmology</i> , <b>2001</b> , 119, 399-404		174
54	Ocular perfusion and age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2001</b> , 79, 108-15		49
53	Evolving pathophysiological paradigms for age related macular degeneration. <i>British Journal of Ophthalmology</i> , <b>2001</b> , 85, 510-2	5.5	6
52	Anti-angiogenic therapy of proliferative diabetic retinopathy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2001</b> , 2, 395-407	4	14
51	Macular pigment optical density in a midwestern sample. <i>Ophthalmology</i> , <b>2001</b> , 108, 730-7	7.3	114
50	Delayed suprachoroidal hemorrhage after glaucoma filtration procedures. <i>Ophthalmology</i> , <b>2001</b> , 108, 1808-11	7.3	89
49	Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. <i>American Journal of Clinical Nutrition</i> , <b>2001</b> , 74, 796-802	7	147
48	Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. <i>Current Opinion in Ophthalmology</i> , <b>2001</b> , 12, 442-9 <sup>5.1</sup>		28
47	Aging affects the retrobulbar circulation differently in women and men. <i>JAMA Ophthalmology</i> , <b>2000</b> , 118, 1076-80		89
46	Olestra consumption is not associated with macular pigment optical density in a cross-sectional volunteer sample in Indianapolis. <i>Journal of Nutrition</i> , <b>2000</b> , 130, 642-7	4.1	16
45	INTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2000</b> , 20, 244-250	3.6	389
44	Vasoprotection as neuroprotection for the optic nerve. <i>Eye</i> , <b>2000</b> , 14 ( Pt 3B), 473-5	4.4	9

43	Endothelin-1-mediated retinal artery vasospasm and the rabbit electroretinogram. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2000</b> , 16, 393-8	2.6	14
42	Changing therapeutic paradigms in CMV retinitis in AIDS. <i>Expert Opinion on Pharmacotherapy</i> , <b>2000</b> , 1, 1343-52	4	2
41	Preliminary experience in the treatment of choroidal melanoma with gamma knife radiosurgery. <i>Journal of Neurosurgery</i> , <b>2000</b> , 93, 177-179	3.2	18
40	Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. <i>Expert Opinion on Investigational Drugs</i> , <b>1999</b> , 8, 2173-2182	5.9	18
39	Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>1999</b> , 15, 425-8	2.6	59
38	Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , <b>1999</b> , 18, 669-87	20.5	133
37	Update on acute and chronic endophthalmitis. <i>Ophthalmology</i> , <b>1999</b> , 106, 2237-8	7.3	18
36	Ginkgo biloba extract increases ocular blood flow velocity. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>1999</b> , 15, 233-40	2.6	101
35	Comparison of intraocular to plasma HIV-1 viral burden in patients with cytomegalovirus retinitis. <i>American Journal of Ophthalmology</i> , <b>1999</b> , 127, 221-3	4.9	8
34	Mitochondrial maculopathy: geographic atrophy of the macula in the MELAS associated A to G 3243 mitochondrial DNA point mutation. <i>American Journal of Ophthalmology</i> , <b>1999</b> , 128, 112-4	4.9	39
33	Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration. <i>American Journal of Ophthalmology</i> , <b>1999</b> , 128, 75-80	4.9	114
32	Repair of retinal detachments due to herpes varicella-zoster virus retinitis. <i>Ophthalmology</i> , <b>1998</b> , 105, 390-1	7.3	3
31	Age-related macular degeneration: a review of experimental treatments. <i>Survey of Ophthalmology</i> , <b>1998</b> , 43, 134-46	6.1	97
30	Presumed macular choroidal watershed vascular filling, choroidal neovascularization, and systemic vascular disease in patients with age-related macular degeneration. <i>American Journal of Ophthalmology</i> , <b>1998</b> , 126, 153-5	4.9	11
29	Evolution of a full-thickness macular hole. <i>American Journal of Ophthalmology</i> , <b>1998</b> , 125, 245-7	4.9	3
28	THE USE OF DYE DILUTION CURVE ANALYSIS IN THE QUANTIFICATION OF INDOCYANINE GREEN ANGIOGRAMS OF THE HUMAN CHOROID. <i>Ophthalmology Clinics of North America</i> , <b>1998</b> , 11, 331-337		4
27	Regulation of retinal and optic nerve blood flow. <i>JAMA Ophthalmology</i> , <b>1998</b> , 116, 1491-5		100
26	Exogenous <i>Aspergillus niger</i> endophthalmitis in a patient with a filtering bleb. <i>Retina</i> , <b>1997</b> , 17, 461-2	3.6	5

25	Subretinal aspiration biopsy of ocular lymphoma. <i>American Journal of Ophthalmology</i> , <b>1997</b> , 123, 420-2	4.9	30
24	Talc embolism: a static retinopathy. <i>American Journal of Ophthalmology</i> , <b>1997</b> , 124, 841-3	4.9	9
23	Acute progressive multifocal Best's disease in a 61-year-old man. <i>American Journal of Ophthalmology</i> , <b>1997</b> , 123, 129-31	4.9	9
22	Blebitis, early endophthalmitis, and late endophthalmitis after glaucoma-filtering surgery. <i>Ophthalmology</i> , <b>1997</b> , 104, 986-95	7.3	143
21	Uveal lymphoid neoplasia: a clinical-pathologic correlation and review of the early form. <i>Survey of Ophthalmology</i> , <b>1997</b> , 41, 467-76	6.1	35
20	Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. <i>Diabetes</i> , <b>1997</b> , 46, 1473-1480	8.9	149
19	EXOGENOUS ASPERGILLUS NIGER ENDOPHTHALMITIS IN A PATIENT WITH A FILTERING BLEB. <i>Retina</i> , <b>1997</b> , 17, 461-462	3.6	11
18	Postvitrectomy positioning complicated by ulnar nerve palsy. <i>American Journal of Ophthalmology</i> , <b>1996</b> , 122, 739-40	4.9	24
17	Serpiginous choroiditis. <i>International Ophthalmology Clinics</i> , <b>1996</b> , 36, 135-43	1.7	21
16	Endophthalmitis following glaucoma filtering surgery. <i>International Ophthalmology Clinics</i> , <b>1996</b> , 36, 87-96	1.7	6
15	Intravitreal toxicity of dental adhesives in the rabbit. <i>Retina</i> , <b>1996</b> , 16, 431-6	3.6	2
14	Severe penetrating eye trauma caused by fish pick accidents. <i>Retina</i> , <b>1996</b> , 16, 219-21	3.6	6
13	Retinal artery occlusion in rabbit eyes using human atheroma. <i>Current Eye Research</i> , <b>1995</b> , 14, 573-8	2.9	2
12	Images in clinical medicine. Herpes simplex virus corneal dendrite. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1743	59.2	
11	Laser photodisruption of visible retinal artery emboli. <i>British Journal of Ophthalmology</i> , <b>1995</b> , 79, 964-5	5.5	5
10	Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. <i>Survey of Ophthalmology</i> , <b>1995</b> , 40, 197-206	6.1	31
9	Bilateral Infantile Cataractogenesis in a Patient With Deficiency of Complex I, A Mitochondrial Electron Transport Chain Enzyme. <i>Journal of Pediatric Ophthalmology and Strabismus</i> , <b>1995</b> , 32, 378-382	0.9	5
8	Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. <i>Annals of Neurology</i> , <b>1991</b> , 30, 550-7	9.4	68

7	Photosensitization of single-strand breaks in pBR322 DNA by rose bengal. <i>Photochemistry and Photobiology</i> , <b>1989</b> , 49, 293-8	3.6	66
6	A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex. <i>Cell</i> , <b>1989</b> , 57, 1095-100	56.2	216
5	A simple method for DNA purification from peripheral blood. <i>Analytical Biochemistry</i> , <b>1988</b> , 174, 485-8	3.1	216
4	Molecular genotypes of the T-cell receptor beta chain in families with multiple sclerosis. <i>Annals of the New York Academy of Sciences</i> , <b>1988</b> , 540, 271-6	6.5	5
3	Photoaddition of chlorpromazine to guanosine-5Tmonophosphate. <i>Photochemistry and Photobiology</i> , <b>1986</b> , 43, 607-13	3.6	27
2	Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes		1
1	Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration1		